

AUROBINDO PHARMA LIMITED
(CIN - L24239TG1986PLC015190)
www.aurobindo.com

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India
Tel: +91 (40) 66721200; Fax: +91 40 23741080; Email: info@aurobindo.com

(All amounts are in ₹ million, unless otherwise stated)

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026				
	Particulars	Quarter ended		
		30.06.2026	31.03.2026	30.06.2025
		Unaudited	Unaudited (Refer note 7)	Unaudited
1	Revenue from operations			
	(a) Net sales/ income from operations	27,816.9	27,469.8	28,221.4
	(b) Other operating income	178.2	395.7	260.3
	Total revenue from operations	27,995.1	27,865.5	28,481.7
2	Other income			
	(a) Foreign exchange gain (net)	729.9	203.5	406.0
	(b) Others	1,689.0	1,937.4	431.7
	Total other income	2,418.9	2,140.9	837.7
3	Total income (1+2)	30,414.0	30,006.4	29,319.4
4	Expenses			
	(a) Cost of materials consumed	12,888.9	12,516.6	13,400.1
	(b) Purchase of stock-in-trade	-	165.2	143.8
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(480.5)	427.9	384.8
	(d) Employee benefits expense	2,959.1	2,927.1	2,829.7
	(e) Finance costs	470.7	472.7	600.0
	(f) Depreciation and amortisation expenses	689.9	719.3	700.2
	(g) Other expenses	3,805.1	4,014.5	3,759.9
	Total expenses	20,333.2	21,243.3	21,818.5
5	Profit before exceptional items and tax (3-4)	10,080.8	8,763.1	7,500.9
6	Exceptional items (refer note 4)	-	-	-
7	Profit before tax (5-6)	10,080.8	8,763.1	7,500.9
8	Tax expense			
	Current tax	2,715.0	1,819.5	1,876.8
	Deferred tax	(6.4)	21.3	32.8
	Total tax expense	2,708.6	1,840.8	1,909.6
9	Profit after tax (7-8)	7,372.2	6,922.3	5,591.3
10	Other comprehensive income			
	Items that will not to be reclassified subsequently to profit or loss:			
	(a) Re-measurement of defined benefit liability	3.6	48.4	(17.6)
	(b) Income-tax relating to items that will not be reclassified to profit or loss	(0.9)	(12.2)	4.4
	Total other comprehensive income/(loss) (net of tax)	2.7	36.2	(13.2)
11	Total comprehensive income (9+10)	7,374.9	6,958.5	5,578.1
12	Paid-up equity share capital (face value ₹ 1 per share)	575.4	580.8	580.8
13	Other equity			
14	Earnings per equity share (face value ₹ 1 per share)			
	(a) Basic (in ₹)	12.75	11.92	9.63
	(b) Diluted (in ₹)	12.75	11.92	9.63



-4-



NOTES:

- 1 The above unaudited standalone financial results of Aurobindo Pharma Limited ("the Company") has been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2 The above unaudited standalone financial results of the Company as reviewed by the Audit Committee have been approved by the Board of Directors at its meeting held on August 05, 2026. The results for the quarter ended June 30, 2026 has been reviewed by our statutory auditors. The statutory auditors of the Company have issued an unmodified conclusion in respect of the limited review for the quarter ended June 30, 2026.
- 3 The Company operates in only one reportable segment viz., 'Pharmaceuticals' in accordance with Ind AS 108, "Operating Segment".
- 4 During the year ended March 31, 2026, the Government of India consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows: Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). The New Labour Codes are effective from November 21, 2025 and introduce changes that include, among other things, setting a uniform definition of wages. The Government is in the process of issuing related rules. The New Labour Codes have implications on employee benefits including gratuity, leave encashment, and other related obligations.
The Company assessed the implications of the New Labour Codes and recognized an incremental cost of ₹ 173.8 million during the year ended March 31, 2026.
- 5 The Board of Directors of Company at their meeting held on April 06, 2026, approved buyback of 5,423,728 fully paid-up equity shares of face value of ₹ 1 each (representing 0.93% of the total number of equity shares of the Company) for an aggregate value not exceeding ₹ 8,000.0 million (buyback size) (excluding transaction cost) at a maximum buyback price of ₹ 1,475 per equity share. Upon completion of the buyback, the Company extinguished the equity shares in compliance with applicable rules and regulations.
Consequently, the paid-up equity share capital has been reduced by ₹ 5.4 million. The aggregate amount paid for buyback is ₹ 8,065.3 million including related expenses.
- 6 The Board of Directors of the Company at its meeting held on April 06, 2026 approved the transfer of domestic branded generic pharmaceutical formulations products business on a going concern basis through a Business Transfer Agreement ("BTA") to Auropharm Limited (previously known as Auro Pharma Limited), a wholly owned subsidiary of the Company on a going concern basis w.e.f April 01, 2026. Accordingly, the net assets of the business have been transferred at the consideration of ₹ 1,432.1 Million to Auropharm Limited.
- 7 The figures for the quarter ended March 31, 2026, are the balancing figures between the audited figures in respect of full financial year ended March 31, 2026 and published year to date figures up to third quarter ended December 31, 2025 and which were subject to limited review by the statutory auditors.

By Order of the Board
For Aurobindo Pharma Limited



K.Nithyananda Reddy
Vice Chairman & Managing Director
DIN-01284195

Place: Hyderabad
Date : August 05, 2026



INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF AUROBINDO PHARMA LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **AUROBINDO PHARMA LIMITED** ("the Company"), for the quarter ended June 30, 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For DELOITTE HASKINS & SELLS

Chartered Accountants
(Firm's Registration No. 008072S)

C Manish Muralidhar

(Partner)
(Membership No. 213649)
(UDIN: 26213649ROKIBQ2934)

Place: Hyderabad
Date: August 05, 2026

**AUROBINDO PHARMA LIMITED**

(CIN - L24239TG1986PLC015190)

www.aurobindo.com

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India

Tel: +91 (40) 66721200; Fax: +91 40 23741080; Email: info@aurobindo.com

(All amounts are in ₹ million, unless otherwise stated)

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

	Particulars	Quarter ended			Year ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		Unaudited	Unaudited (Refer note 12)	Unaudited	Audited
1	Revenue from operations				
	(a) Net sales/ income from operations	91,058.2	87,515.0	77,917.7	3,33,847.4
	(b) Other operating income	445.3	1,018.4	763.7	2,683.4
	Total revenue from operations	91,503.5	88,533.4	78,681.4	3,36,530.8
2	Other income				
	(a) Foreign exchange gain (net)	526.2	-	-	-
	(b) Others	2,116.1	1,170.4	1,053.0	4,920.9
	Total other income	2,642.3	1,170.4	1,053.0	4,920.9
	Total income (1+2)	94,145.8	89,703.8	79,734.4	3,41,451.7
3	Expenses				
	(a) Cost of materials consumed	28,944.0	25,053.5	25,351.6	1,03,051.9
	(b) Purchase of stock-in-trade	9,317.8	9,314.8	8,078.0	34,779.8
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(1,992.3)	(77.6)	(1,037.4)	(2,948.1)
	(d) Employee benefits expense	14,801.5	13,739.8	12,288.0	51,901.7
	(e) Finance costs	1,016.6	982.1	977.5	3,839.7
	(f) Foreign exchange loss (net)	-	481.6	3.9	100.7
	(g) Depreciation, amortisation and impairment expense	4,868.2	4,785.7	4,057.0	17,781.9
	(h) Other expenses (refer note 11)	21,621.9	22,493.5	17,967.0	81,187.5
	Total expenses	78,577.7	76,773.4	67,685.6	2,89,695.1
4	Profit before share of profit/(loss) of associates and joint ventures, exceptional items and tax (1+2-3)	15,568.1	12,930.4	12,048.8	51,756.6
5	Share of profit/(loss) of associates and joint ventures, net of tax	(15.4)	(24.3)	19.2	15.2
6	Profit before exceptional items and tax (4+5)	15,552.7	12,906.1	12,068.0	51,771.8
7	Exceptional items (refer note 8)	401.8	-	-	653.3
8	Profit before tax (6-7)	15,150.9	12,906.1	12,068.0	51,118.5
9	Tax expense				
	Current tax	6,100.1	3,990.3	4,907.2	17,361.4
	Deferred tax	(1,269.5)	(292.6)	(1,081.2)	(1,272.6)
	Total tax expense	4,830.6	3,697.7	3,826.0	16,088.8
10	Profit after tax (8-9)	10,320.3	9,208.4	8,242.0	35,029.7
11	Other comprehensive Income				
	A) Items that will not be reclassified subsequently to profit or loss:				
	i) Re-measurement of defined employee benefit liability	3.6	121.6	(21.9)	73.7
	ii) Equity investments through other comprehensive income – net change in fair value	(81.1)	25.3	12.3	35.5
	iii) Income-tax relating to items that will not be reclassified to profit or loss	17.5	(35.5)	2.8	(27.0)
	B) Items that will be reclassified subsequently to profit or loss:				
	i) Exchange differences on translating the financial statements of foreign operations	(408.7)	7,794.2	4,065.2	19,569.8
	ii) Income-tax on items that will be reclassified subsequently to profit or loss	-	-	-	-
	Total other comprehensive income (net of tax)	(468.7)	7,905.6	4,058.4	19,652.0
12	Total comprehensive income (net of tax) (10+11)	9,851.6	17,114.0	12,300.4	54,681.7
	Attributable to:				
	Owners of the Parent Company	9,856.9	17,118.2	12,305.9	54,699.4
	Non-controlling interest	(5.3)	(4.2)	(5.5)	(17.7)
	Out of total comprehensive income above, Profit after tax attributable to:				
	Owners of the Parent Company	10,325.6	9,212.6	8,247.5	35,047.5
	Non-controlling interest	(5.3)	(4.2)	(5.5)	(17.8)
	Other comprehensive income/(loss) attributable to:				
	Owners of the Parent Company	(468.7)	7,905.6	4,058.4	19,651.9
	Non-controlling interest	-	-	-	0.1
13	Paid-up equity share capital (face value ₹ 1 per share)	575.4	580.8	580.8	580.8
14	Other equity				3,78,328.9
15	Earnings per equity share (face value ₹ 1 per share)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
	(a) Basic (in ₹)	17.86	15.86	14.20	60.34
	(b) Diluted (in ₹)	17.86	15.86	14.20	60.34



NOTES:

- 1 The above unaudited consolidated financial results of Aurobindo Pharma Limited ("the Company") including its subsidiaries (collectively known as "the Group") and its associates and joint ventures have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2 The above unaudited consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on "Consolidated financial statements" and Ind AS 28 on "Investments in Associates and Joint ventures" notified under Section 133 of the Act and Companies (Indian Accounting Standards) Rules, 2015, as amended.
- 3 The above unaudited consolidated financial results of the Group as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on August 05, 2026. The results for the quarter ended June 30, 2026 has been reviewed by our statutory auditors. The statutory auditors of the Company have issued an unmodified opinion in respect of the limited review for the quarter ended June 30, 2026.
- 4 The Group operates in only one reportable segment viz., 'Pharmaceuticals' in accordance with Ind AS 108, "Operating Segment".

5 During the quarter ended June 30, 2026:

- i) The Company, incorporated a step down subsidiary, Arrow Pharma Production SAS, France through Agile Pharma B.V., Netherlands a wholly owned subsidiary of the Company w.e.f. May 21, 2026.
 - ii) The Company invested ₹ 5.2 million to acquire 26% stake in Swarnaakshu Solar Power Private Limited, India making it an associate company w.e.f. June 25, 2026.
 - iii) The Company, incorporated a step down subsidiary, PT Auro Pharm Indonesia through PT Aurogen Pharma Indonesia, a wholly owned subsidiary of the Company w.e.f. July 01, 2026.
- 6 On July 30, 2025, the Company through its wholly owned subsidiary, Aurobindo Pharma USA, Inc. entered into a definitive agreement to acquire 100% membership interest in Lannett Company LLC.

On June 29, 2026 ('Acquisition date') the Company pursuant to above membership purchase agreement completed the acquisition of 100% membership interest in Lannett Company LLC along with its subsidiaries (Silarx Pharmaceuticals Inc, Kremers Urban Pharmaceuticals Inc and Cody Laboratories Inc) for a purchase consideration of ₹ 23,348.8 million (USD 247.1 million) upon satisfaction of customary closing conditions and receipt of the necessary regulatory approvals and has been consolidated with effect from that date. Hence, the results for the quarter ended June 30, 2026, are not comparable to the earlier periods presented. The transaction was accounted for in accordance with Ind AS 103 (Business Combinations), and the initial accounting has been provisionally determined.

- 7 The Board of Directors of the Parent Company at its meeting held on April 06, 2026 approved the transfer of domestic branded generic pharmaceutical formulations products business on a going concern basis through a Business Transfer Agreement ("BTA") to Auropharm Limited (previously known as Auro Pharma Limited), a wholly owned subsidiary of the Company on a going concern basis w.e.f April 01, 2026.

Accordingly, the net assets of the business have been transferred at the consideration of ₹ 1,432.1 million to Auropharm Limited. Since the transaction is with the wholly owned subsidiary of the Company, there is no impact on the unaudited consolidated financial statements.

8 Exceptional item:

- a) For the quarter ended June 30, 2026 includes acquisition and related costs of ₹ 401.8 million (USD 4.3 million) in relation to the acquisition of 100% membership interest of Lannett Company LLC.
 - b) During the year ended March 31, 2026, the Government of India consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows: Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). The New Labour Codes are effective from November 21, 2025 and introduce changes that include, among other things, setting a uniform definition of wages. The Government is in the process of issuing related rules. The New Labour Codes have implications on employee benefits including gratuity, leave encashment, and other related obligations. The Company assessed the implications of the New Labour Codes and recognized an incremental cost of ₹ 653.3 million during the year ended March 31, 2026.
- 9 The Board of Directors of Parent Company at their meeting held on April 06, 2026, approved buyback of 5,423,728 fully paid-up equity shares of face value of ₹ 1 each (representing 0.93% of the total number of equity shares of the parent company) for an aggregate value not exceeding ₹ 8,000.0 million (buyback size) (excluding transaction cost) at a maximum buyback price of ₹ 1,475 per equity share. Upon completion of the buyback, the parent company extinguished the equity shares in compliance with applicable rules and regulations.

Consequently, the paid-up equity share capital has been reduced by ₹ 5.4 million. The aggregate amount paid for buyback is ₹ 8,065.3 million including related expenses.

- 10 Subsequent to the quarter end, on July 23, 2026, the Board of Directors of Apitoria Pharma Private Limited (a wholly owned subsidiary of the Company) approved the acquisition of an 80% ownership interest in the A1 Biochem Group, comprising A1 Biochem Labs (India) Private Limited, A1 Biochem Research (India) Private Limited and A1 Biochem Labs LLC, USA, at an enterprise value of USD 17.0 million on a debt-free and cash-free basis.


The Company will invest USD 13.6 million for its 80% ownership interest in the A1 Biochem Group, subject to certain adjustments and conditions precedent, and the transaction is expected to be completed within 90-120 days.

- 11 During the current quarter, Aurobindo Pharma USA, Inc., a wholly owned subsidiary of the Company recorded net loss on derecognition of lease receivable of ₹ 432.6 million (USD 4.5 million) which is included under the head "Other expenses".

- 12 The figures for the quarter ended March 31, 2026, are the balancing figures between the audited figures in respect of full financial year ended March 31, 2026 and unaudited year to date published figures up to third quarter ended December 31, 2025, which were subject to limited review by the statutory auditors.



By Order of the Board
For Aurobindo Pharma Limited


K. Nithyananda Reddy

Vice Chairman & Managing Director
DIN-01284195



INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF AUROBINDO PHARMA LIMITED

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **AUROBINDO PHARMA LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit after tax and total comprehensive income of its associates and joint ventures for the quarter ended June 30, 2026 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
4. The Statement includes the results of subsidiaries, associates and joint ventures listed in Annexure I.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial information of 22 subsidiaries included in the unaudited consolidated financial results, whose interim financial information reflect total revenues of ₹ 57,315.7 for the quarter ended June 30, 2026, total profit after tax (net) of ₹ 2,286.7 million for the quarter ended June 30, 2026 and total comprehensive income (net) of ₹ 2,286.7 million for the quarter ended June 30, 2026, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of these matters.

μ

2

7. The unaudited consolidated financial results includes the interim financial information of 60 subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect total revenue of ₹ 20,048.8 million for the quarter ended June 30, 2026, total profit after tax (net) of ₹ 157.6 million for the quarter ended June 30, 2026 and total comprehensive profit of ₹ 157.6 million for the quarter ended June 30, 2026, as considered in the Statement. The unaudited consolidated financial results also includes the Group's share of loss after tax of ₹ 15.4 million for the quarter ended June 30, 2026 and total comprehensive loss of ₹ 15.4 million for the quarter ended June 30, 2026, as considered in the Statement, in respect of 3 associates and 3 joint ventures, based on their interim financial information which have not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For **DELOITTE HASKINS & SELLS**
Chartered Accountants
(Firm's Registration No. 008072S)

C Manish Muralidhar
Partner
(Membership No. 213649)
(UDIN: 26213649HBNIVE4592)

Place: Hyderabad
Date: August 05, 2026

Annexure I to the Independent Auditor's Report on Review of Interim Unaudited Consolidated Financial Results

The interim unaudited consolidated financial results include results of the following entities:

S No	Name of Component	Country	Relationship
1	Helix Healthcare B.V.	The Netherlands	Direct Subsidiary
2	APL Pharma Thai Limited	Thailand	Direct Subsidiary
3	Aurobindo Pharma Industria Farmaceutica Ltd	Brazil	Direct Subsidiary
4	Aurobindo Pharma Produtos Farmaceuticos Limitada	Brazil	Direct Subsidiary
5	All Pharma (Shanghai) Trading Co Ltd	China	Direct Subsidiary
6	Aurobindo Pharma USA Inc.	USA	Direct Subsidiary
7	APL Healthcare Limited	India	Direct Subsidiary
8	Auro Peptides Limited	India	Direct Subsidiary
9	Apitoria Pharma Private Limited	India	Direct Subsidiary
10	Auroactive Pharma Private Limited	India	Direct Subsidiary
11	CuraTeQ Biologics Private Limited	India	Direct Subsidiary
12	AuroZest Private Limited	India	Direct Subsidiary
13	Aurobindo Antibiotics Private Limited	India	Direct Subsidiary
14	Eugia Pharma Specialities Limited	India	Direct Subsidiary
15	GLS Pharma Limited	India	Direct Subsidiary
16	TheraNyM Biologics Private Limited	India	Direct Subsidiary
17	Auropharm Limited (formerly known as Auro Pharma Limited)	India	Direct Subsidiary
18	Aurobindo Pharma Foundation	India	Direct Subsidiary
19	Auro Vaccines Private Limited	India	Step-Down Subsidiary
20	Agile Pharma B.V.	The Netherlands	Step-Down Subsidiary
21	Milpharm Limited	United Kingdom	Step-Down Subsidiary
22	Aurobindo Pharma (Malta) Ltd	Malta	Step-Down Subsidiary
23	APL Swift Services (Malta) Ltd	Malta	Step-Down Subsidiary
24	Aurobindo Pharma (Romania) s.r.l	Romania	Step-Down Subsidiary
25	Pharmacin B.V. (Merged with Agile Pharma B.V. w.e.f July 01, 2025)	The Netherlands	Step-Down Subsidiary
26	Aurovitas Pharma Polska	Poland	Step-Down Subsidiary
27	Generis Farmaceutica S.A.	Portugal	Step-Down Subsidiary
28	Generis Phar, Unipessoal Lda	Portugal	Step-Down Subsidiary
29	Aurobindo Pharma (Italia) S.r.l	Italy	Step-Down Subsidiary
30	Arrow Generiques SAS	France	Step-Down Subsidiary
31	1980 Puren Pharma GmbH, Germany	Germany	Step-Down Subsidiary
32	Puren Pharma GmbH & Co., KG	Germany	Step-Down Subsidiary
33	Aurovitas Spain SA	Spain	Step-Down Subsidiary
34	Aurobindo Pharma B.V.	The Netherlands	Step-Down Subsidiary
35	Aurovitas Spol s.r.o	Czech Republic	Step-Down Subsidiary
36	Apotex Europe B.V.	The Netherlands	Step-Down Subsidiary
37	Aurovitas Nederland B.V	The Netherlands	Step-Down Subsidiary
38	Sameko Farma B.V.	The Netherlands	Step-Down Subsidiary
39	Leidapharm B.V.	The Netherlands	Step-Down Subsidiary
40	Marel B.V.	The Netherlands	Step-Down Subsidiary

Deloitte Haskins & Sells

S No	Name of Component	Country	Relationship
41	Pharma Dossier B.V.	The Netherlands	Step-Down Subsidiary
42	Aurobindo NV/SA	Belgium	Step-Down Subsidiary
43	CuraTeQ Biologics s.r.o.	Czech Republic	Step-Down Subsidiary
44	Eugia Pharma B.V.	The Netherlands	Step-Down Subsidiary
45	Eugia Pharma (Malta) Limited	Malta	Step-Down Subsidiary
46	Eugia (UK) Limited	United Kingdom	Step-Down Subsidiary
47	Auro Pharma Inc.	Canada	Step-Down Subsidiary
48	Aurobindo Pharma (Pty) Ltd	South Africa	Step-Down Subsidiary
49	Aurobindo Pharma Japan KK	Japan	Step-Down Subsidiary
50	Aurovida Farmaceutica SA DE CV	Mexico	Step-Down Subsidiary
51	Aurobindo Pharma Colombia S.A.S	Colombia	Step-Down Subsidiary
52	Aurogen South Africa (PTY) Ltd	South Africa	Step-Down Subsidiary
53	Aurobindo Pharma Saudi Arabia Ltd Company	Saudi Arabia	Step-Down Subsidiary
54	Aurovitas Pharma (Taizhou) Ltd	China	Step-Down Subsidiary
55	Aurobindo Pharma FZ-LLC	Dubai	Step-Down Subsidiary
56	Aurosulud SA De CV	Mexico	Step-Down Subsidiary
57	Auro PR Inc.	Puerto Rico	Step-Down Subsidiary
58	Eugia Pharma Inc.	Canada	Step-Down Subsidiary
59	Eugia Pharma (Australia) PTY Limited	Australia	Step-Down Subsidiary
60	Eugia Pharma Industria Farmaceutica Limitada	Brazil	Step-Down Subsidiary
61	Aurobindo Pharma Ukraine LLC	Ukraine	Step-Down Subsidiary
62	Eugia Pharma Colombia S.A.S.	Colombia	Step-Down Subsidiary
63	PT Aurogen Pharma	Indonesia	Step-Down Subsidiary
64	Aurolife Pharma LLC	USA	Step-Down Subsidiary
65	Auro Health LLC	USA	Step-Down Subsidiary
66	Auro AR LLC	USA	Step-Down Subsidiary
67	Auro Vaccines LLC	USA	Step-Down Subsidiary
68	AuroLogistics LLC	USA	Step-Down Subsidiary
69	Acrotech Biopharma Inc	USA	Step-Down Subsidiary
70	Auro Science LLC	USA	Step-Down Subsidiary
71	Auro Packaging LLC	USA	Step-Down Subsidiary
72	Vespyr Brands, LLC	USA	Step-Down Subsidiary
73	Eugia Inc.	USA	Step-Down Subsidiary
74	Eugia US LLC	USA	Step-Down Subsidiary
75	Eugia US Manufacturing LLC	USA	Step-Down Subsidiary
76	Eugia Steriles Private Limited	India	Step-Down Subsidiary
77	Lyfius Pharma Private Limited	India	Step-Down Subsidiary
78	Qule Pharma Private Limited	India	Step-Down Subsidiary
79	Eugia SEZ Private Limited	India	Step-Down Subsidiary
80	Auro Pharma LLC	Russia	Step-Down Subsidiary
81	Purple Bellflower, South Africa	South Africa	Step-Down Subsidiary
82	Ace Laboratories Limited	United Kingdom	Step-Down Subsidiary
83	Cresedemo Pharma LLC (w.e.f. June 13, 2025)	USA	Step-Down Subsidiary
84	Curateq Biologics B.V (w.e.f May 28, 2025)	The Netherlands	Step-Down Subsidiary

Deloitte Haskins & Sells

S No	Name of Component	Country	Relationship
85	Aurobindo Pharma (Malaysia) SDN. BHD. (w.e.f September 17, 2025)	Malaysia	Step-Down Subsidiary
86	CuraTeQ Biologics (Malta) Limited (w.e.f September 26, 2025)	Malta	Step-Down Subsidiary
87	Aurobindo Pharma Chile SpA (w.e.f October 07, 2025)	Chile	Step-Down Subsidiary
88	Eugia Pharma Chile SpA (w.e.f October 07, 2025)	Chile	Step-Down Subsidiary
89	Aurobindo Pharma Philippines Inc (w.e.f January 23, 2026)	Philippines	Step-Down Subsidiary
90	Diadame Pharma SARL (w.e.f January 1, 2026)	Senegal	Step-Down Subsidiary
91	Engenra Biologics Private Limited (w.e.f February 24, 2026)	India	Direct Subsidiary
92	Arrow Pharma Production SAS (w.e.f. 21.05.2026)	France	Step-Down Subsidiary
93	Lannett Company LLC (w.e.f June 29, 2026)	USA	Step-Down Subsidiary
94	Silarx Pharmaceuticals INC (w.e.f June 29, 2026)	USA	Step-Down Subsidiary
95	Kremers Urban Pharmaceuticals INC (w.e.f June 29, 2026)	USA	Step-Down Subsidiary
96	Cody Laboratories INC (w.e.f June 29, 2026)	USA	Step-Down Subsidiary
97	Luoxin Aurovitas Pharm (Chengdu) Co. Ltd.	China	Joint venture
98	Raidurgam Developers Limited	India	Joint venture
99	Tergene Biotech Limited	India	Joint venture
100	NVNR (Ramannapet I) Power Plant Private Limited	India	Associate
101	NVNR (Ramannapet II) Power Plant Private Limited	India	Associate
102	Swarnaakshu Solar Power Private Limited (w.e.f June 25, 2026)	India	Associate